Information provided in the product description is from published literature. Due to the nature of scientific experimentation, your results (e.g., selectivity and effective concentrations) or specific application for this product may differ. If you have questions about how this product fits your application, please contact our technical support staff.
Visit our FAQ
Toll Free Phone (USA and Canada Only): (888) 526-5351
Direct Phone: (734) 975-3888
Product Categories
Provide batch numbers separated by commas to download or request available product inserts, QC sheets, certificates of analysis, data packs, and GC-MS data.
HS-276 is a TGF-β-activated kinase 1 (TAK1) inhibitor (IC50 = 8.25 nM).1 It is selective for TAK1 over a panel of 137 other kinases at 10 µM but does inhibit CDC-like kinase 2 (Clk2), hexokinase (HK), and unc-51-like autophagy activating kinase 2 (ULK2; IC50s = 29, 33, and 63 nM, respectively). HS-276 inhibits LPS-induced increases in secretion of TNF, IL-6, and IL-1β from THP-1 macrophages differentiated by phorbol 12-myristate 13-acetate (PMA; IC50s = 138, 201, and 234 nM, respectively). It inhibits collagen-induced increases in pannus formation, cartilage damage, bone resorption, and periosteal bone formation in a mouse model of rheumatoid arthritis when administered at a dose of 50 mg/kg twice per day.
WARNING This product is not for human or veterinary use.
1. Development and efficacy of an orally bioavailable selective TAK1 inhibitor for the treatment of inflammatory arthritis. ACS Chem. Biol. 17(3), 536-544 (2022).